Edit
Pharmacyclics, an AbbVie Company
http://www.pharmacyclics.com/Last activity: 26.09.2024
Active
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer.
More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.
Review our LinkedIn community guidelines at http://bit.ly/AbbVieSocialGuidelines.
More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.
Review our LinkedIn community guidelines at http://bit.ly/AbbVieSocialGuidelines.
Location: United States, California, Sunnyvale
Employees: 1001-5000
Founded date: 1991
Investors 1
| Date | Name | Website |
| - | Asset Mana... | assetman.c... |
Mentions in press and media 6
| Date | Title | Description |
| 26.09.2024 | A Surfer Without a Degree Is Worth $16 Billion After His Biotech Company's Stock Soared 1,100% in a Year He took classes at UC Santa Barbara in the 1960s but didn't get a degree. Instead, he was focus... | This article originally appeared on Business Insider. A surfer without a college degree has gone from baking cookies to building robots, minting billions in biotech, and ranking among the world's richest people. Bob Duggan, 80, is the co-C... |
| 16.05.2018 | A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash | Thomson Reuters FILE PHOTO: Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana Advertisement Drugmaker Pharmacyclics had tripled the cost of a lifesaving cancer blood treatment when i... |
| 25.09.2015 | Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus | This new round, ostensibly a Series B, has 33 investors participating. The company has yet to return outreach to discuss the company’s activities, and how it’ll use the funding. OrbiMed Advisors led December’s Series A, though other investo... |
| 04.11.2014 | AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology | AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology 04-11-2014 Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological ... |
| 06.06.2007 | Patients, CEOs and ideologues vs. evidence-based medicine | The first time you hear it, “evidence-based medicine” sounds like one of those goofily redundant phrases like “animated cartoon” or “past experience.” Aren’t doctors always carrying out studies of one sort or another? Isn’t medicine evidenc... |
| - | Former Pharmacyclics CEO raises $75M Series B for new immunotherapy startup Corvus | Bay area immuno-oncology startup Corvus Pharmaceuticals just raised an impressive $75 million, SEC filings show – just on the heels of a $33 million Series A fundraise this past December. The startup is led by former Pharmacyclics CEO Richa... |